Online inquiry

IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6592MR)

This product GTTS-WQ6592MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets DPEP3 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001129758.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64180
UniProt ID Q9H4B8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6592MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12648MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ212MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ3562MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ3121MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ13811MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ1502MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ2031MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ13818MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-10987
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW